How I manage frontline transplant-ineligible multiple myeloma
The Multiple Myeloma (MM) is a plasma cells hematological malignancy with a median age of 69 years at diagnosis. The autologous stem cell transplantation is the standard of care for this disease but less than half of newly diagnosed patients are assessed for this treatment due to comorbidities or co...
Main Authors: | Daniele Derudas, Francesca Capraro, Giovanni Martinelli, Claudio Cerchione |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8956 |
Similar Items
-
Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
by: Wenjiao Tang, et al.
Published: (2024-01-01) -
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
by: Francesca Bonello, et al.
Published: (2020-12-01) -
Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
by: Hira Mian, et al.
Published: (2023-02-01) -
How I manage frontline transplant-eligible multiple myeloma in Italy
by: Vittorio Montefusco, et al.
Published: (2020-09-01) -
Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database
by: Rayan Kaedbey, et al.
Published: (2024-06-01)